Buprenorphine transdermal system and quality of life in opioid-experienced patients with chronic low back pain

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 3, 2013, Pages 269-277

  Miller, Kate ^a   Yarlas, Aaron ^a   Wen, Warren ^b   Dain, Bradley ^b   Lynch, Shau Yu ^b   Brennan, Michael J ^c   Ripa, Steven R ^b  

^a QualityMetric Incorporated   (United States)

^b PURDUE PHARMA L P   (United States)

^c The Pain Center of Fairfield   (United States)

Author keywords

Buprenorphine; Butrans ; Health related quality of life; Low back pain; Opioid treatment; Transdermal delivery

Indexed keywords

ANALGESIC AGENT; BUPRENORPHINE; OPIATE; OXYCODONE;

ADULT; ANALGESIA; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; HUMAN; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN ASSESSMENT; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SHORT FORM 36;

ADMINISTRATION, CUTANEOUS; ADULT; ANALGESICS, OPIOID; BUPRENORPHINE; CHRONIC PAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LOW BACK PAIN; MALE; MIDDLE AGED; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TRANSDERMAL PATCH; TREATMENT OUTCOME;

EID: 84873386707     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.767331     Document Type: Article

References (45)

1. Dionne CE, Dunn KM, Croft PR, et al. A consensus approach toward the standardization of back pain definitions for use in prevalence studies. Spine (Phila Pa 1976) 2008;33(1):95-103
2. Buchbinder R, Batterham R, Elsworth G, et al. A validity-Driven approach to the understanding of the personal and societal burden of low back pain: Development of a conceptual and measurement model. Arthritis Res Ther 2011;13(5):R152
3. Ostelo RW, Deyo RA, Stratford P, et al. Interpreting change scores for pain and functional status in low back pain: Towards international consensus regarding minimal important change. Spine (Phila Pa 1976) 2008;33(1):90-4
4. Hoy DG, Bain C, Williams G, et al. A systematic review of the global prevalence of low back pain. Arthritis Rheum 2012;64(6):2028-37
5. Strine TW, Hootman JM. US national prevalence and correlates of low back and neck pain among adults. Arthritis Rheum 2007;57(4):656-65 (Pubitemid 46764057)
6. Asche CV, Kirkness CS, McAdam-Marx C, Fritz JM. The societal costs of low back pain: Data published between 2001 and 2007. J Pain Palliat Care Pharmacother 2007;21(4):25-33 (Pubitemid 47585217)
7. Druss BG, Marcus SC, Olfson M, Pincus HA. The most expensive medical conditions in America. Health Aff (Millwood) 2002;21(4):105-11
8. Rizzo JA, Abbott TA III, Berger ML. The labor productivity effects of chronic backache in the United States. Med Care 1998;36(10):1471-88 (Pubitemid 128456367)
9. Croft PR, Macfarlane GJ, Papageorgiou AC, et al. Outcome of low back pain in general practice: A prospective study. BMJ 1998;316(7141):1356-9 (Pubitemid 28195877)
10. Mersky H, Bogduk N. Classification of chronic pain. 2nd edition. IASP Press; Seattle: 1994
11. Freburger JK, Holmes GM, Agans RP, et al. The rising prevalence of chronic low back pain. Arch Intern Med 2009;169(3):251-8
12. Ekman M, Jonhagen S, Hunsche E, Jonsson L. Burden of illness of chronic low back pain in Sweden: A cross-Sectional, retrospective study in primary care setting. Spine (Phila Pa 1976) 2005;30(15):1777-85 (Pubitemid 41099493)
13. Salaffi F, De Angelis R, Stancati A, Grassi W. Health-related quality of life in multiple musculoskeletal conditions: A cross-Sectional population based epidemiological study. II. The MAPPING study. Clin Exp Rheumatol 2005;23(6):829-39 (Pubitemid 43040511)
14. Veresciagina K, Ambrozaitis KV, Spakauskas B. Health-related quality-of-Life assessment in patients with low back pain using SF-36 questionnaire. Medicina (Kaunas) 2007;43(8):607-13
15. Kosinski MR, Schein JR, Vallow SM, et al. An observational study of health-related quality of life and pain outcomes in chronic low back pain patients treated with fentanyl transdermal system. Curr Med Res Opin 2005;21(6):849-62 (Pubitemid 40896233)
16. Bentsen SB, Wahl AK, Strand LI, Hanestad BR. Relationships between demographic, clinical and pain variables and health-related quality of life in patients with chronic low back pain treated with instrumented fusion. Scand J Caring Sci 2007;21(1):134-43
17. DeVine J, Norvell DC, Ecker E, et al. Evaluating the correlation and responsiveness of patient reported pain with function and quality of life outcomes after spine surgery. Spine (Phila Pa 1976) 2011;36(21 Suppl):S69-74
18. Rabini A, Aprile I, Padua L, et al. Assessment and correlation between clinical patterns, disability and health-related quality of life in patients with low back pain. Eura Medicophys 2007;43(1):49-54
19. Ren XS, Selim AJ, Fincke G, et al. Assessment of functional status, low back disability, and use of diagnostic imaging in patients with low back pain and radiating leg pain. J Clin Epidemiol 1999;52(11):1063-71 (Pubitemid 29469809)
20. Veresciagina K, Ambrozaitis KV, Spakauskas B. The measurements of health-related quality-of-Life and pain assessment in the preoperative patients with low back pain. Medicina (Kaunas) 2009;45(2):111-22
21. Allan L, Richarz U, Simpson K, Slappendel R. Transdermal fentanyl versus sustained release oral morphine in strong-opioid naive patients with chronic low back pain. Spine (Phila Pa 1976) 2005;30(22):2484-90 (Pubitemid 41669082)
22. Huge V, Schloderer U, Steinberger M, et al. Impact of a functional restoration program on pain and health-related quality of life in patients with chronic low back pain. Pain Med 2006;7(6):501-8 (Pubitemid 44762548)
23. Ruoff GE, Rosenthal N, Jordan D, et al. Tramadol/Acetaminophen combination tablets for the treatment of chronic lower back pain: A multicenter, randomized, double-blind, placebo-Controlled outpatient study. Clin Ther 2003;25(4):1123-41 (Pubitemid 36532582)
24. Skljarevski V, Zhang S, Desaiah D, et al. Duloxetine versus placebo in patients with chronic low back pain: A 12-week, fixed-Dose, randomized, double-blind trial. J Pain 2010;11(12):1282-90
25. Szczurko O, Cooley K, Busse JW, et al. Naturopathic care for chronic low back pain: A randomized trial. PLoS One 2007;2(9):e919
26. Practice guidelines for chronic pain management. A report by the American Society of Anesthesiologists Task Force on Pain Management, Chronic Pain Section. Anesthesiology 1997;86(4):995-1004
27. Fourney DR, Andersson G, Arnold PM, et al. Chronic low back pain: A heterogeneous condition with challenges for an evidence-based approach. Spine (Phila Pa 1976) 2011;36(21 Suppl):S1-9
28. White AP, Arnold PM, Norvell DC, et al. Pharmacologic management of chronic low back pain: Synthesis of the evidence. Spine (Phila Pa 1976) 2011;36(21 Suppl):S131-43
29. Martell BA, O'Connor PG, Kerns RD, et al. Systematic review: Opioid treatment for chronic back pain: Prevalence, efficacy, and association with addiction. Ann Intern Med 2007;146(2):116-27 (Pubitemid 351640015)
30. Schofferman J, Mazanec D. Evidence-informed management of chronic low back pain with opioid analgesics. Spine J 2008;8(1):185-94 (Pubitemid 350299287)
31. Przeklasa-Muszynska A, Dobrogowski J. Transdermal buprenorphine for the treatment of moderate to severe chronic pain: Results from a large multicenter, non-interventional post-marketing study in Poland. Curr Med Res Opin 2011;27(6):1109-17
32. Muriel C, Failde I, Mico JA, et al. Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: A multicenter, open-Label, uncontrolled, prospective, observational clinical study. Clin Ther 2005;27(4):451-62 (Pubitemid 40732652)
33. Griessinger N, Sittl R, Likar R. Transdermal buprenorphine in clinical practice-A post-marketing surveillance study in 13,179 patients. Curr Med Res Opin 2005;21(8):1147-56 (Pubitemid 41140716)
34. Public policy statement on the rights and responsibilities of health care professionals in the use of opioids for the treatment of pain: A consensus document from the American Academy of Pain Medicine, the American Pain Society, and the American Society of Addiction Medicine. Pain Med 2004;5(3):301-2
35. Dhalla IA, Mamdani MM, Sivilotti ML, et al. Prescribing of opioid analgesics and related mortality before and after the introduction of long-Acting oxycodone. CMAJ 2009;181(12):891-6
36. Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: A cohort study. Ann Intern Med 2010;152(2):85-92
37. Steiner D, Munera C, Hale M, et al. Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: A randomized, double-blind study. J Pain 2011;12(11):1163-73
38. Steiner DJ, Sitar S, Wen W, et al. Efficacy and safety of the seven-Day buprenorphine transdermal system in opioid-naive patients with moderate to severe chronic low back pain: An enriched, randomized, double-blind, placebo-Controlled study. J Pain Symptom Manage 2011;42(6):903-17
39. Gordon A, Callaghan D, Spink D, et al. Buprenorphine transdermal system in adults with chronic low back pain: A randomized, double-blind, placebo-Controlled crossover study, followed by an open-Label extension phase. Clin Ther 2010;32(5):844-60
40. Gordon A, Rashiq S, Moulin DE, et al. Buprenorphine transdermal system for opioid therapy in patients with chronic low back pain. Pain Res Manag 2010;15(3):169-78
41. Maruish ME. editor. User's manual for the SF-36v2 health survey. 3rd edition. QualityMetric, Inc; Lincoln, RI: 2011
42. Kosinski M, Zhao SZ, Dedhiya S, et al. Determining minimally important changes in generic and disease-Specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000;43(7):1478-87 (Pubitemid 30452465)
43. Agresti A, Coull BA. Approximate is better than "Exact" for interval estimation of binomial proportions. Am Stat 1998;52:119-26
44. Wallace M, Thipphawong J. Open-Label study on the long-Term efficacy, safety, and impact on quality of life of OROS hydromorphone ER in patients with chronic low back pain. Pain Med 2010;11(10):1477-88
45. Yarlas A, Miller K, Wen W, et al. A Randomized, Placebo-Controlled Study of the Impact of the 7-Day Buprenorphine Transdermal System on Health-Related Quality of Life in Opioid-Naive Patients with Moderate-To-Severe Chronic Low Back Pain. J Pain 2012; [Epub ahead of print